Apigenin Attenuates Insulin-Like Growth Factor-I Signaling in an Autochthonous Mouse Prostate Cancer Model
暂无分享,去创建一个
[1] J. DiGiovanni,et al. Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis , 2011, Molecular carcinogenesis.
[2] B. Aggarwal,et al. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals , 2010, Cancer and Metastasis Reviews.
[3] S. Shukla,et al. Apigenin: A Promising Molecule for Cancer Prevention , 2010, Pharmaceutical Research.
[4] S. Freier,et al. Antisense oligonucleotide targeting of insulin‐like growth factor‐1 receptor (IGF‐1R) in prostate cancer , 2010, The Prostate.
[5] R. Goldbohm,et al. Dietary flavonol, flavone and catechin intake and risk of colorectal cancer in the Netherlands Cohort Study , 2009, International journal of cancer.
[6] M. Gadelha,et al. IGF-I, insulin and prostate cancer. , 2009, Arquivos brasileiros de endocrinologia e metabologia.
[7] B. Grzybowski,et al. The Chemopreventive Bioflavonoid Apigenin Inhibits Prostate Cancer Cell Motility through the Focal Adhesion Kinase/Src Signaling Mechanism , 2009, Cancer Prevention Research.
[8] Johann S de Bono,et al. Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer , 2009, Clinical Cancer Research.
[9] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[10] S. Shukla,et al. Apigenin suppresses insulin‐like growth factor I receptor signaling in human prostate cancer: An in vitro and in vivo study , 2009, Molecular carcinogenesis.
[11] S. Shukla,et al. Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study. , 2008, Carcinogenesis.
[12] K. Ahmed,et al. Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells , 2008, Molecular and Cellular Biochemistry.
[13] B. Rosner,et al. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer , 2007, International journal of cancer.
[14] M. Resnick,et al. Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. , 2007, Cancer research.
[15] F. Berrino,et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. , 2007, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[16] S. Shukla,et al. Apigenin-induced Cell Cycle Arrest is Mediated by Modulation of MAPK, PI3K-Akt, and Loss of Cyclin D1 Associated Retinoblastoma Dephosphorylation in Human Prostate Cancer Cells , 2007, Cell cycle.
[17] D. Spandidos,et al. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. , 2006, International journal of oncology.
[18] M. Slomiany,et al. Hypoxia-Inducible Factor-1-Dependent and -Independent Regulation of Insulin-Like Growth Factor-1-Stimulated Vascular Endothelial Growth Factor Secretion , 2006, Journal of Pharmacology and Experimental Therapeutics.
[19] B. Lokeshwar,et al. Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence? , 2006, Urologic oncology.
[20] Han You,et al. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. , 2006, Genes & development.
[21] Anil Mishra,et al. Up‐regulation of insulin‐like growth factor binding protein‐3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[22] Maria Parpinel,et al. Flavonoids and Breast Cancer Risk in Italy , 2005, Cancer Epidemiology Biomarkers & Prevention.
[23] V. Adhami,et al. Oral Consumption of Green Tea Polyphenols Inhibits Insulin-Like Growth Factor-I–Induced Signaling in an Autochthonous Mouse Model of Prostate Cancer , 2004, Cancer Research.
[24] F. Miró,et al. Unbalanced activation of ERK1/2 and MEK1/2 in apigenin-induced HeLa cell death. , 2004, Experimental cell research.
[25] T. Byzova,et al. Metastatic Properties of Prostate Cancer Cells are Controlled by VEGF , 2004, Cell communication & adhesion.
[26] Myoung H. Kim. Flavonoids inhibit VEGF/bFGF‐induced angiogenesis in vitro by inhibiting the matrix‐degrading proteases , 2003, Journal of cellular biochemistry.
[27] Tsuey-Ming Chen,et al. Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.
[28] L. Bégin,et al. Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. , 2002, The Journal of urology.
[29] M. Kattan,et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Oh,et al. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. , 2001, Cancer research.
[31] J. Jorcano,et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[32] O. Cussenot,et al. VEGF overexpression in clinically localized prostate tumors and neuropilin‐1 overexpression in metastatic forms , 2000, International journal of cancer.
[33] M B Katan,et al. Dietary flavonoids: intake, health effects and bioavailability. , 1999, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[34] B. Foster,et al. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. , 1999, Cancer research.
[35] C. Mantzoros,et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.
[36] Y. Wong,et al. Sex hormone‐induced prostatic carcinogenesis in the Noble rat: The role of insulin‐like growth factor‐1 (IGF‐1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer , 1998, The Prostate.
[37] C. Bucana,et al. Regulation of distinct steps of angiogenesis by different angiogenic molecules. , 1998, International journal of oncology.
[38] Meir J. Stampfer,et al. Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .
[39] Z. Kelman. PCNA: structure, functions and interactions , 1997, Oncogene.
[40] R. Geahlen,et al. Inhibition of protein-tyrosine kinase activity by flavanoids and related compounds. , 1989, Journal of natural products.
[41] J. Thrasher,et al. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. , 1996, The Journal of clinical endocrinology and metabolism.